Trading Signals: SAGE Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Fri. Dec. 22, 2023)(SAGE Therapeutics Inc)
| SAGE latest price $170.3200 (1.96%) ($167.3400 - $170.7900) on Thu. May. 16, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.11% (three month average) | RSI | 52 | Latest Price | $170.3200(1.96%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | SAGE declines -0.4% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support SAGE advance at 0% a week (0% probability) IBB(49%) IWO(46%) XBI(45%) IWC(43%) IWM(43%) | Factors Impacting SAGE price | SAGE will decline at least -1.055% in a week (0% probabilities). VXX(-13%) VIXM(-8%) TLT(-7%) UUP(-5%) IGOV(-4%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.055% (StdDev 2.11%) | Hourly BBV | 0 () | Intraday Trend | 1.4% | | | |
|
5 Day Moving Average | $166.69(2.18%) | 10 Day Moving Average | $167.96(1.41%) | 20 Day Moving Average | $167.3(1.81%) | To recent high | -0.4% | To recent low | 16.5% | Market Cap | $8.846b | | | | SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA. |